eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Janssen-Cilag Ltd
50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone: +44 (0)1494 567 567
Fax: +44 (0)1494 567 568
WWW: http://www.janssen.co.uk
WWW: http://www.janssen-medinfo.co.uk
Medical Information Direct Line: +44 (0)800 731 8450
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +44 (0)800 731 5550

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 22/09/2011
PIL Velcade

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to drug interactions
Updated on 09/08/2011 and displayed until 22/09/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contra-indications
Updated on 20/01/2011 and displayed until 09/08/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 13/07/2010 and displayed until 20/01/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 13/07/2010 and displayed until 13/07/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 08/06/2010 and displayed until 13/07/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to drug interactions
Updated on 29/04/2010 and displayed until 08/06/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 17/06/2009 and displayed until 29/04/2010
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to dosage and administration
Updated on 16/09/2008 and displayed until 17/06/2009
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to dosage and administration
Updated on 06/08/2008 and displayed until 16/09/2008
Reasons for adding or updating:
  • Change to Marketing Authorisation Holder
Updated on 20/05/2008 and displayed until 06/08/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Addition of separate PILs covering individual presentations
Updated on 11/09/2007 and displayed until 20/05/2008
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 05/09/2006 and displayed until 11/09/2007
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
Updated on 11/08/2005 and displayed until 05/09/2006
Reasons for adding or updating:
  • Change to Further Information section
Updated on 01/07/2005 and displayed until 11/08/2005
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 11/05/2005 and displayed until 01/07/2005
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to side-effects
Updated on 18/11/2004 and displayed until 11/05/2005
Reasons for adding or updating:
  • Change to storage instructions
  • Change to date of revision
Updated on 27/05/2004 and displayed until 18/11/2004
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  bortezomib mannitol boronic ester